Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$49 Mln
P/E Ratio
--
P/B Ratio
1.8
Industry P/E
--
Debt to Equity
0.57
ROE
-0.08 %
ROCE
-5.19 %
Div. Yield
0 %
Book Value
2.96
EPS
-0.24
CFO
$-0.03 Mln
EBITDA
$2.16 Mln
Net Profit
$-11.60 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ImmuCell (ICCC)
| 4.47 | 9.21 | -2.18 | 7.17 | -15.06 | 5.28 | -1.17 |
|
BSE Sensex*
| 1.98 | 3.76 | 5.22 | 9.18 | 11.28 | 21.10 | 11.17 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
ImmuCell (ICCC)
| 1.17 | -16.56 | -23.75 | 34.45 | 15.53 | -26.91 | -19.74 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,559.25 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and... Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Address: 56 Evergreen Drive, Portland, ME, United States, 04103 Read more
President, CEO, Principal Financial Officer, Treasurer, Secretary & Director
Mr. Michael F. Brigham
President, CEO, Principal Financial Officer, Treasurer, Secretary & Director
Mr. Michael F. Brigham
Headquarters
Portland, ME
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ImmuCell Corporation (ICCC) stood at $ 45 Mln as on 31-Dec-24
The share price of ImmuCell Corporation (ICCC) is $5.38 (NASDAQ) as of 21-Apr-2025 16:00 EDT. ImmuCell Corporation (ICCC) has given a return of -15.06% in the last 3 years.
ImmuCell Corporation (ICCC) has a market capitalisation of $ 49 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of ImmuCell Corporation (ICCC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ImmuCell Corporation (ICCC) and enter the required number of quantities and click on buy to purchase the shares of ImmuCell Corporation (ICCC).
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Address: 56 Evergreen Drive, Portland, ME, United States, 04103
The CEO & director of Mr. Michael F. Brigham. is ImmuCell Corporation (ICCC), and CFO & Sr. VP is Mr. Michael F. Brigham.
There is no promoter pledging in ImmuCell Corporation (ICCC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| ImmuCell Corporation (ICCC) | Ratios |
|---|---|
|
Return on equity(%)
|
-8.39
|
|
Operating margin(%)
|
-6.2
|
|
Net Margin(%)
|
-8.14
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ImmuCell Corporation (ICCC) was $0 Mln.
$-0.12
(
